Surveillance and Health Services Research, American Cancer Society, Atlanta, Georgia.
Cancer Control Interventions, American Cancer Society, Atlanta, Georgia.
Cancer. 2018 Dec 15;124(24):4720-4730. doi: 10.1002/cncr.31763. Epub 2018 Sep 26.
Human papillomavirus vaccination (HPVV) prevents several types of cancer. The American Cancer Society recently established a goal that by 2026, 80% of adolescents will be up to date (UTD) before their 13th birthday. However, the number in need of vaccination to reach this goal is unknown. This study estimated the number of additional adolescents (11-12 years old) who need HPVV for 80% prevalence to be reached by 2026.
The study used de-identified and publicly available data and exempt from institutional review board approval and informed consent. The 2016 National Immunization Survey for Teens was used to estimate the baseline HPVV prevalence. Linear growth to 80% HPVV prevalence by 2026 was applied to set intermediate targets. US Census Bureau data were used for population projections. This study estimated the cumulative number of additional adolescents 11 to 12 years old who would need to become UTD (ie, receive 2 doses) by first subtracting the number who would need to be vaccinated to achieve an intermediate target prevalence from the estimated number currently compliant and then summing these numbers between 2018 and 2026.
Nationwide, an additional 7.62 million males (95% confidence interval [CI], 6.78 million to 8.40 million) and an additional 6.77 million females (95% CI, 5.95 million to 7.55 million), aged 11 to 12 years, would need to receive 2 doses of the vaccine between 2018 and 2026 for 80% prevalence to be achieved. Most adolescents not UTD (80%) also needed to initiate vaccination, and more than 90% recently visited a health care provider.
It is estimated that at least 14.39 million additional adolescents aged 11 to 12 years in the United States will need to receive 2 doses of HPVV for a UTD HPVV prevalence of 80% to be achieved by 2026. To reach this goal, improvements in facilitators of HPVV initiation, including physician recommendations and parental acceptability, are needed.
人乳头瘤病毒疫苗接种(HPV 疫苗)可预防多种癌症。美国癌症协会最近设定了一个目标,到 2026 年,80%的青少年在 13 岁生日前完成疫苗接种。然而,要达到这一目标需要接种疫苗的人数尚不清楚。本研究估计,到 2026 年,为达到 80%的流行率,需要额外接种 HPV 疫苗的青少年(11-12 岁)人数。
本研究使用了去标识和公开可用的数据,且免于机构审查委员会批准和知情同意。使用 2016 年全国青少年免疫调查来估计基线 HPV 疫苗接种率。线性增长到 2026 年 80%的 HPV 疫苗接种率,以设定中期目标。美国人口普查局的数据用于人口预测。本研究估计了 2018 年至 2026 年期间,11 至 12 岁需要额外接种 2 剂疫苗的累计青少年人数,方法是先从估计的符合条件的人数中减去达到中期目标接种率所需的人数,然后将这些数字相加。
全国范围内,还需要额外接种 2 剂疫苗的男性青少年有 762 万人(95%置信区间 [CI]:678 万至 840 万),女性青少年有 677 万人(95%CI:595 万至 755 万),年龄在 11 至 12 岁,以实现 80%的流行率。大多数未接种疫苗的青少年(80%)也需要开始接种疫苗,而且超过 90%的人最近去过医疗机构。
据估计,到 2026 年,美国至少有 1439 万 11 至 12 岁的青少年需要接种 2 剂 HPV 疫苗,才能达到 80%的 HPV 疫苗接种率。要实现这一目标,需要改善 HPV 疫苗接种的促进因素,包括医生的建议和家长的接受程度。